Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Joycelyn J. X., Chan, Jack J., Choo, Su Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548260/
https://www.ncbi.nlm.nih.gov/pubmed/28943627
http://dx.doi.org/10.3390/diseases3040306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548260/
https://www.ncbi.nlm.nih.gov/pubmed/28943627
http://dx.doi.org/10.3390/diseases3040306

Ejemplares similares